Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: OlaszországFázis nélkül

Predictors of Major Adverse Limb Events After Endovascular Iliac Stenting: a Real-world Cohort Study

A legfontosabb adatok

Ki végzi
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Hol
Milan (Olaszország)A helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
98 fő, tervezett
Kezdés
2026. jún. 16.
Tervezett befejezés
2026. júl. 16.
A vizsgálat típusa
Megfigyeléses
A vizsgált kezelések
  • Iliac stenting
A regiszteradat frissítve
2026. június 30.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with narrowed or blocked iliac arteries (the main arteries to the legs) who were treated with a stent. It looks back at their records to find what predicts serious leg problems afterwards.

Életkor
18 years and older
Nem
Men and women
A betegség stádiuma
Peripheral artery disease with symptoms: leg pain when walking that limits daily life (Rutherford category 2-3) or chronic limb-threatening ischaemia (Rutherford category 4-6). The narrowing or blockage is in the common and/or external iliac artery and was shown on CT angiography, MR angiography or angiography.
Korábbi kezelés
Symptoms did not improve with optimal medical therapy. People must have had iliac artery stenting as the main treatment, on a lesion not treated before. People cannot join if this artery part had a stent before.

A részvétel fő kizáró okai

  • Open surgery on the iliac arteries as the main treatment, such as aorto-bifemoral bypass or endarterectomy
  • A stent placed before in the same iliac segment
  • Treatment mainly for an aorto-iliac aneurysm (a bulging artery), including EVAR or fenestrated endografts
  • Combined procedures with bypass surgery below the groin
  • Missing clinical, procedure or follow-up data, or lost to follow-up

A regiszter feltételei, szó szerint

Mind a 12 feltétel megnézéseKevesebb

Ki vehet részt

  • Adult patients aged ≥18 years, of both male and female sex
  • Presence of haemodynamically significant stenosis or occlusion of the common iliac artery (CIA) and/or external iliac artery (EIA), documented by computed tomography angiography, magnetic resonance angiography, or diagnostic angiography
  • Symptomatic peripheral artery disease, including lifestyle-limiting intermittent claudication (Rutherford category 2-3) or chronic limb- threatening ischaemia (CLTI; Rutherford category 4-6), refractory to optimal medical therapy
  • Treatment with endovascular iliac artery stenting (covered or uncovered; balloon-expandable or self-expanding devices) as the primary revascularisation strategy
  • De novo iliac lesions only
  • Availability of complet

Ki nem vehet részt

  • Primary open surgical revascularisation of the iliac axis (e.g., aorto- bifemoral bypass or endarterectomy)
  • Previous stenting of the target iliac segment (in-stent restenosis cases excluded)
  • Hybrid procedures with concomitant infrainguinal bypass surgery
  • Aorto-iliac aneurysmal disease as the primary indication for treatment (including EVAR or fenestrated endografts)
  • Incomplete clinical, procedural, or follow-up data preventing assessment of study endpoints
  • Loss to follow-up without documented clinical outcomes

Helyszínek itt: Olaszország

  • IRCCS Galeazzi Sant'Ambrogio HospitalMilan, OlaszországContact: Elena Cittera Dr.Résztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

Peripheral arterial disease involving the iliac arteries is a common manifestation of systemic atherosclerosis and a major cause of lifestyle-limiting claudication and chronic limb-threatening ischemia. Endovascular iliac artery stenting has become the preferred treatment strategy for most iliac lesions, including complex TransAtlantic Inter-Society Consensus II (TASC II) C and D lesions, owing to high technical success rates and lower perioperative morbidity compared with open surgical reconstruction.

A teljes eredeti leírásKevesebb

Despite widespread adoption of endovascular treatment, available evidence regarding predictors of major adverse limb events (MALE) after iliac artery stenting remains limited, particularly in unselected real-world populations with substantial comorbidity burden. Patient-related factors, including frailty, may contribute to post-procedural outcomes in addition to lesion-related characteristics.

This retrospective single-center cohort study will evaluate clinical outcomes following endovascular iliac artery stenting in consecutive adult patients treated at IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan, Italy. The study will assess the occurrence of major adverse limb events (MALE), primary patency, peri-procedural complications, target lesion revascularization, restenosis or occlusion, and all-cause mortality. Clinical, anatomical, and procedural factors associated with adverse limb outcomes, including frailty assessed by the modified five-item Frailty Index (mFI-5), will also be investigated.

A vizsgált kezelések

  • Iliac stenting

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Predictors of Major Adverse Limb Events After Endovascular Iliac Stenting: a Real-world Cohort Study (PREMISE-ILIAC Study)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. június 30.